NCT07227298

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

• Status: Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 162 (estimated)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Conditions

• Advanced/Metastatic Non-Small Cell Lung Cancer
• Carcinoma, Non-Small Cell Lung
• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
BIOLOGICAL	PF-08634404	-Concentrate for solution for infusion
BIOLOGICAL	Sigvotatug Vedotin	-Powder for concentrate for solution for infusion. Single use vial
BIOLOGICAL	Combination Agent 1	-Powder for concentrate for solution for infusion. Single use vial.

Timeline

• Start date: 2026-01-30
• Primary completion: 2029-03-08
• Completion: 2033-08-23
• First posted: 2025-11-12
• Last updated: 2026-04-08

Locations

25 sites across 4 countries: United States, Japan, Puerto Rico, Taiwan

Regulatory

• FDA-regulated drug study